

August 6, 2020

Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Mr. Hari K
Asst. Vice President - Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (East), Mumbai – 400 051

Ref: BSE Scrip Code -506690: NSE Symbol - UNICHEMLAB

<u>Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Tolterodine Tartrate Tablets, USP 1 mg and 2 mg.

Thanking you,

For UNICHEM LABORATORIES LIMITED,

PRADEEP BHANDARI Head- Legal & Company Secretary



Mumbai, Thursday, August 6, 2020

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval for its Tolterodine Tartrate Tablets, USP 1 mg and 2 mg from the United States Food and Drug Administration (USFDA) to market a generic version of DETROL® (tolterodine tartrate) tablets of Pfizer Inc.

Tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. The product will be commercialized from Unichem's Goa Plant.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at www.unichemlabs.com

For more information please contact:

Mr. Pradeep Bhandari Ph: +91-22-66888 404

E-mail: pradeep.bhandari@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.